Market closedNon-fractional
Verve Therapeutics/VERV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Verve Therapeutics
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Ticker
VERV
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
255
Website
www.vervetx.com
VERV Metrics
BasicAdvanced
$432M
Market cap
-
P/E ratio
-$2.83
EPS
1.94
Beta
-
Dividend rate
Price and volume
Market cap
$432M
Beta
1.94
Financial strength
Current ratio
19.823
Quick ratio
19.561
Long term debt to equity
10.883
Total debt to equity
12.636
Management effectiveness
Return on assets (TTM)
-20.28%
Return on equity (TTM)
-36.03%
Valuation
Price to revenue (TTM)
22.262
Price to book
0.74
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-2.384
Growth
Revenue change (TTM)
379.79%
Earnings per share change (TTM)
-9.41%
3-year earnings per share growth
-49.45%
What the Analysts think about VERV
Analyst Ratings
Majority rating from 11 analysts.
VERV Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$5.6M
9.80%
Net income
-$49M
0.83%
Profit margin
-869.64%
-8.17%
VERV Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.87
-$0.72
-$0.69
-$0.59
-
Expected
-$0.92
-$0.92
-$0.82
-$0.71
-$0.68
Surprise
-5.23%
-21.57%
-16.06%
-17.25%
-
VERV News
AllArticlesVideos
The Schall Law Firm Initiates Inquiry Into Allegations Against Verve Therapeutics Inc And Encourages Investors Who Suffered Losses To Start Communication
Accesswire·6 hours ago
The Schall Law Firm Commences Inquiry Into Allegations Against Verve Therapeutics Inc And Suggests Investors With Losses To Initiate Communication
Accesswire·2 days ago
Investigation Into Claims Against Verve Therapeutics Inc Started By The Schall Law Firm And Investors With Losses Are Advised To Begin Contact
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verve Therapeutics stock?
Verve Therapeutics (VERV) has a market cap of $432M as of July 06, 2024.
What is the P/E ratio for Verve Therapeutics stock?
The price to earnings (P/E) ratio for Verve Therapeutics (VERV) stock is 0 as of July 06, 2024.
Does Verve Therapeutics stock pay dividends?
No, Verve Therapeutics (VERV) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Verve Therapeutics dividend payment date?
Verve Therapeutics (VERV) stock does not pay dividends to its shareholders.
What is the beta indicator for Verve Therapeutics?
Verve Therapeutics (VERV) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Verve Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.